|
Asthma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The SNP rs3910901, located in the 5' upstream region of ELF5, was found to have a weak association (p = 0.043) with asthma in the odds ratio analysis.
|
25648666 |
2016 |
|
Asthma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Genetic linkage studies suggest that ESE-2 and ESE-3, which encode epithelium-specific Ets-domain-containing transcription factors, are candidate asthma susceptibility genes.
|
18475289 |
2008 |
|
Cystic Fibrosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
E74-like factor 5 (ELF5) and ETS-homologous factor (EHF) are epithelial selective ETS family transcription factors (TFs) encoded by genes at chr11p13, a region associated with cystic fibrosis (CF) lung disease severity.
|
31557407 |
2019 |
|
Malignant neoplasm of breast
|
0.070 |
Biomarker
|
disease |
BEFREE |
These findings establish Elf5 not only as a key cell lineage regulator during normal mammary gland development, but also as a suppressor of EMT and metastasis in breast cancer.
|
23086238 |
2012 |
|
Malignant neoplasm of breast
|
0.070 |
Biomarker
|
disease |
BEFREE |
ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor Cells.
|
26717410 |
2015 |
|
Malignant neoplasm of breast
|
0.070 |
Biomarker
|
disease |
BEFREE |
E74-like factor 5 (Elf5) has been associated with tumor suppression in breast cancer.
|
25629735 |
2015 |
|
Malignant neoplasm of breast
|
0.070 |
Biomarker
|
disease |
BEFREE |
ELF5 also plays key roles in malignancy, particularly in basal-like and endocrine-resistant forms of breast cancer.
|
26738740 |
2016 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
This work is the first to suggest that ELF5 has tumor suppressor activity in the kidney.
|
21787113 |
2011 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
The injection of EWSR1/ELF5-transduced NIH3T3 cells into NSG-SCID mice systematically induced the development of tumors in vivo.
|
27627705 |
2016 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Elf5 is a transcription factor known to regulate critical developmental processes and has been shown to act as a tumour suppressor in multiple cancers.
|
31002388 |
2019 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Myeloid-derived suppressor cells, a group of immature neutrophils recently identified as mediators of vasculogenesis and metastasis, were recruited to the tumor in response to ELF5.
|
26717410 |
2015 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
BACKGROUND E74-like factor 5 (ELF5) plays a key role in the processes of cell differentiation, apoptosis, and occurrence of tumors.
|
30696803 |
2019 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
E74-like factor 5 (Elf5) has been associated with tumor suppression in breast cancer.
|
25629735 |
2015 |
|
Breast Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
These findings establish Elf5 not only as a key cell lineage regulator during normal mammary gland development, but also as a suppressor of EMT and metastasis in breast cancer.
|
23086238 |
2012 |
|
Breast Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor Cells.
|
26717410 |
2015 |
|
Breast Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
ELF5 also plays key roles in malignancy, particularly in basal-like and endocrine-resistant forms of breast cancer.
|
26738740 |
2016 |
|
Breast Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
E74-like factor 5 (Elf5) has been associated with tumor suppression in breast cancer.
|
25629735 |
2015 |
|
Neoplasm Metastasis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
However, the effect of ELF5 on metastasis and invasion in human ovarian cancer remains poorly understood.
|
30696803 |
2019 |
|
Neoplasm Metastasis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
The transcription factor E74-like factor 5 (ELF5) is a potent antioncogene that can prevent epithelial-mesenchymal transition (EMT) and metastasis in prostate cancer (PCa).
|
28287091 |
2017 |
|
Neoplasm Metastasis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
These findings establish Elf5 not only as a key cell lineage regulator during normal mammary gland development, but also as a suppressor of EMT and metastasis in breast cancer.
|
23086238 |
2012 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Our study demonstrates the unique distribution of Elf5<sup>+</sup> cells in multiple adult organs, which will facilitate future studies investigating the function of Elf5 in these tissues during homeostasis, repair and cancer.
|
31002388 |
2019 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Our study demonstrates the unique distribution of Elf5<sup>+</sup> cells in multiple adult organs, which will facilitate future studies investigating the function of Elf5 in these tissues during homeostasis, repair and cancer.
|
31002388 |
2019 |
|
Carcinoma
|
0.020 |
Biomarker
|
group |
BEFREE |
In our cohort, 47% of all carcinomas were positive for Elf5, with a significantly higher proportion of Elf5 positive cases occurring in the younger age groups (p = 0.0061).
|
29396764 |
2018 |
|
Carcinoma
|
0.020 |
Biomarker
|
group |
BEFREE |
ELF5 mRNA was decreased in 94% of lesions tested and ELF5 protein was undetectable in 40/40 kidney-derived carcinomas.
|
21787113 |
2011 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Our data suggest that ELF5 may play roles in mammary, lung, prostate and/or kidney function, and possibly also in tumorigenesis.
|
9840936 |
1998 |